SIGMA RECEPTORS AND DOPAMINE NEUROTRANSMISSION
SIGMA RECEPTORS AND DOPAMINE NEUROTRANSMISSION
批准号:
2654383
负责人:
J. Michael Walker
金额:
$19.71万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1996
资助国家:
美国
项目状态:
已结题
起止时间:
1996-05-01 至 1999-01-31
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (Adapted from applicant's abstract): Sigma receptors, a novel
class of putative neurotransmitter receptors, have been extensively
characterized in binding studies, but relatively less is known about
their functions in the central nervous system. Indeed, establishment of
the function of these sites would greatly strengthen the argument that
they serve as a signalling mechanism in the brain. Previous work and
work from the investigators laboratories has supported the hypothesis
that one function of sigma receptors is to regulate dopamine
neurotransmission. The study of sigma-dopamine interactions is important
for several reasons: (1) dopamine activity has been hypothesized to be
involved in the expression of schizophrenic symptoms, (2) the motor side
effects of antipsychotic drug treatment, such as tardive dyskinesia may
be related to alterations in dopamine neurotransmission, (3)
antipsychotic drugs that produce tardive dyskinesia, such as
haloperidol, have high affinity for both dopamine and sigma receipts,
(4) sigma ligands have been shown to affect dopamine neurotransmission.
The proposed studies will analyze the role of sigma receptors in
dopamine neurotransmission within the nigrostriatal system. These
studies will address the nature of the interaction from three
perspectives: (1) behavioral, using the rat turning model, (2)
neurochemical, using microdialysis with electrochemical detection to
measure in vivo dopamine release; and (3) electrophysiological, with
measurements of firing rate and pattern following administration of
sigma ligands. The proposed studies aims to elucidate the sites and
mechanisms of action of sigma ligands within the nigrostriatal dopamine
system. The proposed research examines the effects of putative sigma
antagonists and the possibility of interactions between sigma and NMDA
receptors in the nigrostriatal system These issues will be addressed in
both cell body and terminal regions by examining the effects of dopamine
and NMDA antagonists, and the effects of sigma ligands on NMDA-evoked
changes in physiology or neurochemistry. The results of these
experiments may provide a better understanding of the role of sigma
receptors as a signalling mechanism within the nigrostriatal system and
the possible mechanisms by which sigma-active antipsychotics produce
movement disorders.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Role of endogenous vanilloids and cannabinoids in pain
-
批准号:7485422
-
项目类别:
-
资助金额:$3.75万
-
财政年份:2005
-
负责人:J. Michael Walker
-
依托单位:
Role of endogenous vanilloids and cannabinoids in pain
-
批准号:7050563
-
项目类别:
-
资助金额:$32.03万
-
财政年份:2005
-
负责人:J. Michael Walker
-
依托单位:
Role of endogenous vanilloids and cannabinoids in pain
-
批准号:6930256
-
项目类别:
-
资助金额:$34.09万
-
财政年份:2005
-
负责人:J. Michael Walker
-
依托单位:
Role of endogenous vanilloids and cannabinoids in pain
-
批准号:7195065
-
项目类别:
-
资助金额:$31.1万
-
财政年份:2005
-
负责人:J. Michael Walker
-
依托单位:
LABORATORY PRIMATE NEWSLETTER: PSYCH WELL BEING
-
批准号:6982637
-
项目类别:
-
资助金额:$6.57万
-
财政年份:2003
-
负责人:J. Michael Walker
-
依托单位:
PAIN MODULATION BY ENDOGENOUS CANNABINOIDS
-
批准号:6719041
-
项目类别:
-
资助金额:$21.8万
-
财政年份:2000
-
负责人:J. Michael Walker
-
依托单位:
PAIN MODULATION BY ENDOGENOUS CANNABINOIDS
-
批准号:6350539
-
项目类别:
-
资助金额:$30.58万
-
财政年份:2000
-
负责人:J. Michael Walker
-
依托单位:
PAIN MODULATION BY ENDOGENOUS CANNABINOIDS
-
批准号:7004889
-
项目类别:
-
资助金额:$11.52万
-
财政年份:2000
-
负责人:J. Michael Walker
-
依托单位:
PAIN MODULATION BY ENDOGENOUS CANNABINOIDS
-
批准号:6051687
-
项目类别:
-
资助金额:$32.46万
-
财政年份:2000
-
负责人:J. Michael Walker
-
依托单位:
PAIN MODULATION BY ENDOGENOUS CANNABINOIDS
-
批准号:6628355
-
项目类别:
-
资助金额:$32.35万
-
财政年份:2000
-
负责人:J. Michael Walker
-
依托单位:
PAIN MODULATION BY ENDOGENOUS CANNABINOIDS
-
批准号:6597375
-
项目类别:
-
资助金额:$5.0万
-
财政年份:2000
-
负责人:J. Michael Walker
-
依托单位:
PAIN MODULATION BY ENDOGENOUS CANNABINOIDS
-
批准号:6497830
-
项目类别:
-
资助金额:$31.41万
-
财政年份:2000
-
负责人:J. Michael Walker
-
依托单位:
PRECIPITATED CANNABINOID WITHDRAWAL
-
批准号:2803611
-
项目类别:
-
资助金额:$5.83万
-
财政年份:1997
-
负责人:J. Michael Walker
-
依托单位:
PRECIPITATED CANNABINOID WITHDRAWAL
-
批准号:2882614
-
项目类别:
-
资助金额:$25.32万
-
财政年份:1997
-
负责人:J. Michael Walker
-
依托单位:
PRECIPITATED CANNABINOID WITHDRAWAL
-
批准号:2668170
-
项目类别:
-
资助金额:$20.1万
-
财政年份:1997
-
负责人:J. Michael Walker
-
依托单位:
PRECIPITATED CANNABINOID WITHDRAWAL
-
批准号:2013658
-
项目类别:
-
资助金额:$21.24万
-
财政年份:1997
-
负责人:J. Michael Walker
-
依托单位:
SIGMA RECEPTORS AND DOPAMINE NEUROTRANSMISSION
-
批准号:2377424
-
项目类别:
-
资助金额:$18.97万
-
财政年份:1996
-
负责人:J. Michael Walker
-
依托单位:
SIGMA RECEPTORS AND DOPAMINE NEUROTRANSMISSION
-
批准号:2123503
-
项目类别:
-
资助金额:$20.19万
-
财政年份:1996
-
负责人:J. Michael Walker
-
依托单位:
SIGMA RECEPTORS AND DOPAMINE NEUROTRANSMISSION
-
批准号:2860034
-
项目类别:
-
资助金额:$2.5万
-
财政年份:1996
-
负责人:J. Michael Walker
-
依托单位:
NEUROLOGICAL BASIS OF PAIN--ROLE OF CANNABINOIDS
-
批准号:2416364
-
项目类别:
-
资助金额:$19.76万
-
财政年份:1995
-
负责人:J. Michael Walker
-
依托单位:
国内基金
海外基金
登录
查看更多内容
DRD2/ERK/β-catenin信号联合Dopamine/ERK/TH调节环介导慢性应激促进脑胶质瘤恶性进展的研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:周秀萍
-
依托单位:
11C-N-CH3-Dopamine PET/MRI心脏神经显像对射血分数保留的心衰的实验研究
-
批准号:82171969
-
项目类别:面上项目
-
资助金额:56万元
-
批准年份:2021
-
负责人:王雪梅
-
依托单位:
11C-N-CH3-Dopamine心肌Micro PET/CT显像对糖尿病心脏自主神经病变的评估
-
批准号:82060323
-
项目类别:地区科学基金项目
-
资助金额:34.0万元
-
批准年份:2020
-
负责人:何玉林
-
依托单位:
11C-N-CH3-Dopamine神经显像对心肌"缺血记忆"的实验研究
-
批准号:81460271
-
项目类别:地区科学基金项目
-
资助金额:46.0万元
-
批准年份:2014
-
负责人:王雪梅
-
依托单位:
11C-dopamine PET/CT显像对急性心肌缺血状况下交感神经功能变化的实验研究
-
批准号:81060019
-
项目类别:地区科学基金项目
-
资助金额:26.0万元
-
批准年份:2010
-
负责人:王雪梅
-
依托单位: